Skip to main content

Research Repository

Advanced Search

Outputs (9)

A European consensus recommendation on the management of delayed methotrexate elimination: supportive measures, leucovorin rescue and glucarpidase treatment (2024)
Journal Article
Bielack, S. S., Soussain, C., Fox, C. P., Houillier, C., Murciano, T., Osborne, W., Zinzani, P. L., Rizzari, C., & Schwartz, S. (2024). A European consensus recommendation on the management of delayed methotrexate elimination: supportive measures, leucovorin rescue and glucarpidase treatment. Journal of Cancer Research and Clinical Oncology, 150(10), Article 441. https://doi.org/10.1007/s00432-024-05945-6

High-dose methotrexate (HDMTX) is used in the treatment of a range of adult and childhood cancers. Although HDMTX can provide effective anti-tumor activity with an acceptable safety profile for most patients, delayed methotrexate elimination (DME) de... Read More about A European consensus recommendation on the management of delayed methotrexate elimination: supportive measures, leucovorin rescue and glucarpidase treatment.

Real‐world outcomes of patients with relapsed/refractory large B‐cell lymphoma receiving second‐line therapy in England (2024)
Journal Article
Fox, C. P., Townsend, W., Gribben, J. G., Menne, T., Kalakonda, N., Williams, P., Toron, F., Tyas, E., Cooper, M., Rickards, J., & Radford, J. (2024). Real‐world outcomes of patients with relapsed/refractory large B‐cell lymphoma receiving second‐line therapy in England. eJHaem, 5(5), 992-997. https://doi.org/10.1002/jha2.970

Autologous stem-cell transplantation (ASCT) is standard therapy for relapsed/refractory large B-cell lymphoma (R/R LBCL), but many patients are either ineligible or unable to receive it. This retrospective study characterized outcomes in R/R LBCL, de... Read More about Real‐world outcomes of patients with relapsed/refractory large B‐cell lymphoma receiving second‐line therapy in England.

Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study (2024)
Journal Article
Dupuis, J., Bachy, E., Morschhauser, F., Cartron, G., Fukuhara, N., Daguindau, N., Casasnovas, R.-O., Snauwaert, S., Gressin, R., Fox, C. P., d'Amore, F. A., Staber, P. B., Tournilhac, O., Bouabdallah, K., Thieblemont, C., André, M., Rai, S., Ennishi, D., Gkasiamis, A., Nishio, M., …Lemonnier, F. (2024). Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study. Lancet Haematology, 11(6), e406-e414. https://doi.org/10.1016/S2352-3026%2824%2900102-9

Follicular helper T-cell lymphomas (TFHL) harbour frequent alterations in genes that regulate DNA methylation. Preliminary reports suggest that treatment with 5-azacitidine has clinical activity in patients with relapsed or refractory TFHL. We aimed... Read More about Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study.

Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up (2024)
Journal Article
Ferreri, A., Illerhaus, G., Doorduijn, J., Auer, D., Bromberg, J., Calimeri, T., Cwynarski, K., Fox, C., Hoang-Xuan, K., Malaise, D., Ponzoni, M., Schorb, E., Soussain, C., Specht, L., Zucca, E., Buske, C., Jerkeman, M., & Dreyling, M. (2024). Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 35(6), 491-507. https://doi.org/10.1016/j.annonc.2023.11.010

Discontinuation of anti-tumour necrosis factor alpha treatment owing to blood test abnormalities, and cost-effectiveness of alternate blood monitoring strategies (2024)
Journal Article
Abhishek, A., Stevenson, M. D., Nakafero, G., Grainge, M. J., Evans, I., Alabas, O., Card, T., Taal, M. W., Aithal, G. P., Fox, C. P., Mallen, C. D., van der Windt, D. A., Riley, R. D., Warren, R. B., & Williams, H. C. (2024). Discontinuation of anti-tumour necrosis factor alpha treatment owing to blood test abnormalities, and cost-effectiveness of alternate blood monitoring strategies. British Journal of Dermatology, 190(4), 559-564. https://doi.org/10.1093/bjd/ljad430

Background: There is no evidence base to support the use of 6-monthly monitoring blood tests for the early detection of liver, blood and renal toxicity during established anti-tumour necrosis factor alpha (TNFα) treatment. Objectives: To evaluate the... Read More about Discontinuation of anti-tumour necrosis factor alpha treatment owing to blood test abnormalities, and cost-effectiveness of alternate blood monitoring strategies.

Patient and health professional views on risk-stratified monitoring of immune-suppressing treatment in adults with inflammatory diseases (2024)
Journal Article
Fuller, A., Hancox, J., Williams, H. C., Card, T., Taal, M. W., Aithal, G. P., Fox, C. P., Mallen, C. D., Maxwell, J. R., Bingham, S., Vedhara, K., & Abhishek, A. (in press). Patient and health professional views on risk-stratified monitoring of immune-suppressing treatment in adults with inflammatory diseases. Rheumatology, Article keae175. https://doi.org/10.1093/rheumatology/keae175

Objective
To explore the acceptability of an individualised risk-stratified approach to monitoring for target-organ toxicity in adult patients with immune-mediated inflammatory diseases established on immune-suppressing treatment(s).

Methods
Adu... Read More about Patient and health professional views on risk-stratified monitoring of immune-suppressing treatment in adults with inflammatory diseases.

Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation (2024)
Journal Article
Abhishek, A., Grainge, M., Card, T., Williams, H. C., Taal, M. W., Aithal, G. P., Fox, C. P., Mallen, C. D., Stevenson, M. D., Nakafero, G., & Riley, R. (2024). Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation. RMD Open, 10(1), Article e003980. https://doi.org/10.1136/rmdopen-2023-003980

Background Sulfasalazine-induced cytopenia, nephrotoxicity and hepatotoxicity is uncommon during long-term treatment. Some guidelines recommend 3 monthly monitoring blood tests indefinitely during long-term treatment while others recommend stopping m... Read More about Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation.

A Delphi study to determine the epidemiology and clinical management of patients treated with HDMTX who develop methotrexate (MTX) delayed elimination in France, Germany, Italy, and the UK (2024)
Journal Article
Bielack, S., Fox, C. P., Hoang‐Xuan, K., Giró‐Perafita, A., & Rizzari, C. (2024). A Delphi study to determine the epidemiology and clinical management of patients treated with HDMTX who develop methotrexate (MTX) delayed elimination in France, Germany, Italy, and the UK. Health Science Reports, 7(1), Article e1749. https://doi.org/10.1002/hsr2.1749

Introduction: High‐dose methotrexate (HDMTX) is administered for the treatment of some malignancies. Serious complications after the administration of HDMTX are rare, but occasionally MTX may precipitate in the renal tubes causing a delayed eliminati... Read More about A Delphi study to determine the epidemiology and clinical management of patients treated with HDMTX who develop methotrexate (MTX) delayed elimination in France, Germany, Italy, and the UK.